Home > Oncology > WCLC 2022 > WCLC 2022 Congress Round-Up > First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC

First results of sotorasib plus pembrolizumab in KRAS p.G12C-mutated NSCLC

Presented By
Dr Bob Li, Memorial Sloan Kettering Cancer Center, NY, USA
Conference
WCLC 2022
Trial
Phase 1, CodeBreaK 100/101
Doi
https://doi.org/10.55788/c073aab9
Low-dose sotorasib as lead-in therapy, followed by pembrolizumab, demonstrated promising safety and efficacy data in patients with KRAS p.G12C-mutated advanced non-small cell lung cancer (NSCLC). Therefore, these results from the phase 1b CodeBreaK 100/101 study will lead to further exploration of this combination [1]. “Sotorasib is an approved monotherapy in the US, EU, and other countries for patients with previously treated KRAS p.G12C-mutated advanced NSCLC,” said Dr Bob Li (Memorial Sloan Kettering Cancer Center, NY, USA). The CodeBreaK 100/101 study (NCT03600883) explored combinations of sotorasib, from 120 mg to 960 mg once daily, with either atezolizumab or pembrolizumab in patients with previously treated KRAS p.G12C-mutated NSCLC (n=58). Sotorasib was administered as lead-in therapy followed by combination with one of the PD-1 i...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on